Protagonist Therapeutics Inc (NASDAQ:PTGX) was the target of a large drop in short interest in October. As of October 31st, there was short interest totalling 1,050,000 shares, a drop of 5.4% from the September 30th total of 1,110,000 shares. Based on an average trading volume of 203,900 shares, the short-interest ratio is currently 5.1 days. Currently, 5.2% of the shares of the stock are short sold.
Several analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, November 14th. Svb Leerink reiterated an “outperform” rating on shares of Protagonist Therapeutics in a research report on Tuesday, August 13th. Nomura reiterated a “buy” rating and set a $29.00 price target on shares of Protagonist Therapeutics in a research report on Sunday, August 11th. HC Wainwright set a $23.00 price target on shares of Protagonist Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 2nd. Finally, BidaskClub lowered shares of Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, November 9th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $19.60.
NASDAQ PTGX opened at $10.20 on Tuesday. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 0.07. The firm has a market capitalization of $293.83 million, a price-to-earnings ratio of -5.86 and a beta of 1.74. The firm’s 50 day simple moving average is $11.71 and its 200 day simple moving average is $11.90. Protagonist Therapeutics has a 1 year low of $5.49 and a 1 year high of $16.67.
A number of institutional investors have recently modified their holdings of PTGX. BlackRock Inc. boosted its position in Protagonist Therapeutics by 271.6% in the second quarter. BlackRock Inc. now owns 1,017,421 shares of the company’s stock valued at $12,321,000 after buying an additional 743,632 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Protagonist Therapeutics by 99.1% in the second quarter. JPMorgan Chase & Co. now owns 558,729 shares of the company’s stock valued at $6,693,000 after buying an additional 278,066 shares in the last quarter. VHCP Management III LLC boosted its position in Protagonist Therapeutics by 32.5% in the second quarter. VHCP Management III LLC now owns 1,072,348 shares of the company’s stock valued at $12,986,000 after buying an additional 263,025 shares in the last quarter. VHCP Management II LLC boosted its position in Protagonist Therapeutics by 57.3% in the second quarter. VHCP Management II LLC now owns 426,781 shares of the company’s stock valued at $5,168,000 after buying an additional 155,404 shares in the last quarter. Finally, D. E. Shaw & Co. Inc. boosted its position in Protagonist Therapeutics by 54.1% in the second quarter. D. E. Shaw & Co. Inc. now owns 397,278 shares of the company’s stock valued at $4,811,000 after buying an additional 139,550 shares in the last quarter. Hedge funds and other institutional investors own 71.27% of the company’s stock.
About Protagonist Therapeutics
Protagonist Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops peptide-based product candidates to address unmet medical needs in hematology and gastroenterology. The company is developing PTG-300, an injectable hepcidin mimetic that is in Phase II clinical trial for the treatment of patients with beta-thalassemia by targeting the chronic anemia; PTG-200, an antagonist peptide product candidate, which has completed Phase I clinical trial to treat inflammatory bowel disease (IBD); and PN-943, an oral, alpha-4-beta-7 specific integrin antagonist that is in Phase I clinical trial for treating IBD.
Recommended Story: What is the 52-week high/low?
Receive News & Ratings for Protagonist Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
